Why is iRay Technology Co., Ltd. ?
- The company has been able to generate a Return on Capital Employed (avg) of 32.57% signifying low profitability per unit of total capital (equity and debt)
- Poor long term growth as Net Sales has grown by an annual rate of 22.99% and Operating profit at 18.57% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 13.25% signifying low profitability per unit of shareholders funds
- CASH AND EQV(HY) Highest at CNY 7,496.1 MM
- DEBT-EQUITY RATIO (HY) Lowest at -1 %
- INVENTORY TURNOVER RATIO(HY) Highest at 1.79 times
- Over the past year, while the stock has generated a return of 19.01%, its profits have risen by 48.6% ; the PEG ratio of the company is 7.7
- At the current price, the company has a high dividend yield of 0.5
How much should you hold?
- Overall Portfolio exposure to iRay Technology Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is iRay Technology Co., Ltd. for you?
High Risk, Low Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
Highest at CNY 7,496.1 MM
Lowest at -1 %
Highest at 1.79 times
Highest at 2.48 times
Highest at CNY 984.77 MM
Highest at CNY 374.02 MM
Highest at CNY 280.61 MM
Highest at CNY 227.89 MM
Highest at CNY 0.76
Grown by 14.7% (YoY
Highest at CNY 34.57 MM
Here's what is working for iRay Technology Co., Ltd.
Net Sales (CNY MM)
Net Sales (CNY MM)
Operating Profit (CNY MM)
Pre-Tax Profit (CNY MM)
Net Profit (CNY MM)
EPS (CNY)
Cash and Cash Equivalents
Debt-Equity Ratio
Inventory Turnover Ratio
Debtors Turnover Ratio
Here's what is not working for iRay Technology Co., Ltd.
Interest Paid (CNY MM)
Raw Material Cost as a percentage of Sales






